Singapore markets closed

Straits Times Index
3,307.90
-6.15(-0.19%)
S&P 500
5,308.13
+4.86(+0.09%)
Dow
39,806.77
-196.82(-0.49%)
Nasdaq
16,794.88
+108.91(+0.65%)
Bitcoin USD
71,185.94
+4,156.52(+6.20%)
CMC Crypto 200
1,540.91
+52.37(+3.52%)

IRWD Nov 2024 5.000 put

OPR - OPR Delayed price. Currency in USD

Add to watchlist

0.5700

0.0000

(0.00%)

As of 09:30AM EDT. Market open.

Business Wire
Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
BOSTON, May 21, 2024--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, will present late-breaking data during the 2024 Digestive Disease Week® (DDW) meeting from its pivotal Phase III clinical trial, STARS, which evaluated the efficacy and safety of once-weekly subcutaneous apraglutide in adult patients with short bowel syndrome with intestinal failure (SBS-IF). These findings build on the positive topline data that Ironwood previously announced in February 2024. B
Simply Wall St.
US$16.33: That's What Analysts Think Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Is Worth After Its Latest Results
It's been a sad week for Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ), who've watched their investment drop 14% to...
GuruFocus.com
Ironwood Pharmaceuticals Reports Mixed Q1 2024 Results Amid Key Clinical Advancements
Revenue Falls Short of Expectations While Clinical Trials Show Promising Outcomes